‘Clinically Negligible’ Residual Kidney Function Still Beneficial
Even at very low levels, residual kidney function in hemodialysis patients clears uremic solutes.
Even at very low levels, residual kidney function in hemodialysis patients clears uremic solutes.
Each 1 standard deviation in baseline uric acid levels was associated with a significant 80% increased odds of rapid kidney function decline.
Patients in the lowest quartiles of urinary uromodulin had increased risks of end-stage renal disease and rapid kidney function decline.
In a study, end-stage renal disease was 31% more likely to develop in CKD patients with versus without anemia.
From 1995 to 2015, the prevalence of hypertension and diabetes among patients starting hemodialysis increased from 67.9% to 87.6% and from 43.1% to 59.6%, respectively.
In a study, end-stage renal disease developed in 56% of patients discharged from a hospital with acute kidney injury requiring dialysis.
High levels of parathyroid hormone and fibroblast growth factor 23 in CKD patients are associated with need for renal replacement therapy or a 50% or greater decline in eGFR.
After adjusting for confounders, patients on intensive home hemodialysis and recipients of deceased-donor kidneys showed no significant difference in death risk
Timing of AKI after urgent percutaneous coronary intervention affects risk of significant kidney function loss 1 year after the procedure.
CKD patients in the 3rd and 4th quartiles of c-terminal serum fibroblast growth factor 23 had a 74% and 73% higher risk for anemia compared with those in the 1st quartile.